Literature DB >> 17570788

The deflux procedure reduces the incidence of urinary tract infections in patients with vesicoureteral reflux.

George M Wadie1, Michael V Tirabassi, Richard A Courtney, Kevin P Moriarty.   

Abstract

PURPOSE: The aim of this study was to review the experience of a single institution with the Deflux (Q-Med Scandinavia; Uppsala, Sweden) procedure and assess its effectiveness in reducing the incidence of urinary tract infections (UTIs) in children with vesicoureteric reflux (VUR).
MATERIALS AND METHODS: After institutional review board approval, the charts of 100 patients with VUR, who presented between June 2003 and June 2005, were prospectively reviewed. Data collected included: demographics, the number of preoperative and postoperative UTIs, a radiologic grade of VUR on a voiding cystourethrogram (VCUG) and the presence of VUR on a radionuclide VCUG 3 months after the procedure. Patients were continued on oral antibiotics until urine culture at 3 months was negative and no reflux was demonstrated on VCUG. The student's t test was used for data analysis.
RESULTS: The mean age was 3.8 +/- 0.3 years, and 76% were girls. From 155 ureters treated, 10 had Grade I reflux, 42 Grade II, 76 Grade III, 25 Grade IV, and 2 Grade V. A second injection was required in 22 ureters (14.2%). The overall success rate of the procedure (Grade 0 reflux at 3 months) was 77.4% after the first injection and 83.9% after a second injection. The success rate per grade was: 100% for Grade I, 88.1% for Grade II, 86.8% for Grade III, 64% for Grade IV, and 50% for Grade V. The mean follow-up was 446 +/- 20 days. The mean volume injected/ureter was 0.6 +/- 0.03 mL. Thirteen (13) patients had UTIs after the procedure, compared to 75 before. There was a 5-fold reduction in the incidence of UTIs/year, from a mean of 0.68 +/- 0.09 pre- to 0.12 +/- 0.04 postinjection (P = 0.001). The majority of UTIs were caused by Escherichia coli (74% pre- and 82% postinjection).
CONCLUSIONS: We conclude that the Deflux procedure is effective not only in eliminating VUR on radiologic studies, but also in reducing the incidence of UTIs and antibiotic use in children with VUR.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17570788     DOI: 10.1089/lap.2006.0073

Source DB:  PubMed          Journal:  J Laparoendosc Adv Surg Tech A        ISSN: 1092-6429            Impact factor:   1.878


  13 in total

1.  Management of Vesicoureteral Reflux by Endoscopic Injection of Dextranomer/Hyaluronic Acid in Adults.

Authors:  Timothy W Stark; John M Lacy; David M Preston
Journal:  Rev Urol       Date:  2016

2.  Endoscopic treatment of vesicoureteral reflux: current practice and the need for multifactorial assessment.

Authors:  Göran Läckgren; Arne Stenberg
Journal:  Ther Adv Urol       Date:  2009-08

Review 3.  The impact of vesicoureteral reflux treatment on the incidence of urinary tract infection.

Authors:  George M Wadie; Kevin P Moriarty
Journal:  Pediatr Nephrol       Date:  2011-03-06       Impact factor: 3.714

4.  Is availability of endoscopy changing initial management of vesicoureteral reflux?

Authors:  Caleb P Nelson; Hillary L Copp; Julie Lai; Christopher S Saigal
Journal:  J Urol       Date:  2009-07-22       Impact factor: 7.450

Review 5.  Controversies in the management of vesicoureteral reflux: the rationale for the RIVUR study.

Authors:  Ranjiv Mathews; Myra Carpenter; Russell Chesney; Alejandro Hoberman; Ron Keren; Tej Mattoo; Marva Moxey-Mims; Lee Nyberg; Saul Greenfield
Journal:  J Pediatr Urol       Date:  2009-07-01       Impact factor: 1.830

6.  [Long-term results after endoscopic subureteral injection for VUR using dextranomer/hyaluronic acid copolymer : a five years experience].

Authors:  J Seibold; M Werther; K-D Sievert; A Stenzl
Journal:  Urologe A       Date:  2010-04       Impact factor: 0.639

7.  Endoscopic bulking materials for the treatment of vesicoureteral reflux: a review of our 20 years of experience and review of the literature.

Authors:  Boris Chertin; Stanislav Kocherov; Leonid Chertin; Alaeddin Natsheh; Amicur Farkas; Ofer Z Shenfeld; Sarel Halachmi
Journal:  Adv Urol       Date:  2011-04-06

8.  An Open-Label, Noncomparative, Multicenter Study to Evaluate Efficacy and Safety of NASHA/Dx Gel as a Bulking Agent for the Treatment of Fecal Incontinence.

Authors:  Giuseppe Dodi; Johannes Jongen; Fernando de la Portilla; Manoj Raval; Donato F Altomare; Paul-Antoine Lehur
Journal:  Gastroenterol Res Pract       Date:  2010-12-27       Impact factor: 2.260

9.  Has the data efflux regarding the promising outcome following injection of deflux changed the management of adult vesicoureteral reflux?

Authors:  D E Zilberman; Y Mor
Journal:  Adv Urol       Date:  2009-03-10

10.  Treatment of vesicoureteral reflux after puberty.

Authors:  J Christopher Austin
Journal:  Adv Urol       Date:  2009-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.